PROGRAMME AND PRICES 2024
You can download the programme and prices here as pdf: “ECAT Programme and prices 2024“
# Prices are excluding VAT and including shipping costs by regular service.
ANNUAL SUBSCRIPTION
|
||
| Mandatory for each participant. | ||
Description |
Price
|
Product
|
| Annual Subscription Fee | 147.00 | 101 |
MAIN PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
M1 |
M2 |
M3 |
M4 |
||||
| Thrombophilia – I: Antithrombin (activity and antigen), Protein C (activity [chromogenic and clotting] and antigen), Protein S activity, Protein S antigen (total and free) |
4 | √ | √ | √ | √ | 412.50 | 402 |
| Thrombophilia – II APC Resistance |
4 | √ | √ | √ | √ | 167.00 | 417 |
| Coagulation Factor – I Factor VIII (clot and chromogenic activity), IX (clot and chromogenic activity), XI:C and XII:C |
4 | √ | √ | √ | √ | 208.50 | 406 |
| Coagulation Factor – II Factor II:C, V:C, VII:C and X:C |
4 | √ | √ | √ | √ | 208.50 | 407 |
| Von Willebrand Factor parameters (antigen, ristocetin cofactor activity, activity, collagen binding, multimers, Factor VIII) |
4 | √ | √ | √ | √ | 313.50 | 408 |
| ADAMTS13 – I (activity and antigen) | 4 | √ | √ | √ | √ | 219.50 | 409 |
| ADAMTS13 – II (antibodies) | 2 | √ | √ | 143.75 | 410 | ||
| ADAMTS13 – III (functional inhibitor) | 1 | √ | 104.50 | 419 | |||
| Factor XIII (activity and antigen) | 4 | √ | √ | √ | √ | 156.25 | 411 |
| Fibrinolysis – I Plasminogen, Antiplasmin |
4 | √ | √ | √ | √ | 151.50 | 412 |
| Fibrinolysis – II t-PA, PAI-1 |
4 | √ | √ | √ | √ | 151.50 | 413 |
LUPUS PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
L1 |
L2 |
L3 |
L4 |
||||
| Lupus Anticoagulant / Antiphospholipid Antibodies | 4 | √ | √ | √ | √ | 198.50 | 404 |
D-DIMER PROGRAMME |
|||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
D1 |
D2 |
D3 |
D4 |
||||
| D-Dimer | 4 | √ | √ | √ | √ | 151.50 | 405 |
SCREEN PROGRAMME |
|||||||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||||||
S1 |
S2 |
S3 |
S4 |
S5 |
S6 |
S7 |
S8 |
||||
| Screen-I: APTT, PT/INR and Fibrinogen | 8 | √ | √ | √ | √ | √ | √ | √ | √ | 264.00 | 501 |
| Screen-II: Thrombin Time, Reptilase Time | 8 | √ | √ | √ | √ | √ | √ | √ | √ | 264.00 | 502 |
APTT / PT MIXING TEST PROGRAMME |
|||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
Mix-1 |
Mix-2 |
Mix-3 |
Mix-4 |
||||
| APTT / PT Mixing Test | 4 | √ | √ | √ | √ | 220.00 | 503 |
HAEMOPHILIA PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
H1 |
H2 |
H3 |
H4 |
||||
| Haemophilia Factor VIII (clot and chromogenic activity), Factor IX (clot and chromogenic activity) |
4 | √ | √ | √ | √ | 266.50 | 418 |
| Factor VIII inhibitor | 2 | √ | √ | 206.50 | 202 | ||
| Factor IX Inhibitor | 2 | √ | √ | 206.50 | 201 | ||
| Emicizumab | 2 | √ | √ | 206.50 | 223 | ||
| Kovaltry (Bayer) | 2 | √ | √ | 205.00 | 228 | ||
| Jivi (Bayer) | 2 | √ | √ | 205.00 | 229 | ||
| Esperoct (Novo Nordisk) | 2 | √ | √ | 205.00 | 230 | ||
| NovoEight (Novo Nordisk) | 2 | √ | √ | 205.00 | 231 | ||
| Refixia (Novo Nordisk) | 2 | √ | √ | 205.00 | 232 | ||
FDP PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
F1 |
F2 |
F3 |
F4 |
||||
| Fibrin(ogen) Degradation Products | 4 | √ | √ | √ | √ | 151.50 | 420 |
ANTICOAGULATION PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
A1 |
A2 |
A3 |
A4 |
||||
| Unfractionated Heparin Monitoring (anti-Xa) |
4 | √ | √ | √ | √ | 136.00 | 414 |
| Low-Molecular Weight Heparin Monitoring (anti-Xa) | 4 | √ | √ | √ | √ | 136.00 | 415 |
| Orgaran (anti-Xa) | 2 | √ | √ | 69.50 | 205 | ||
| Fondaparinux (anti-Xa) | 2 | √ | √ | 69.50 | 206 | ||
| Rivaroxaban (anti-Xa) | 2 | √ | √ | 69.50 | 207 | ||
| Apixaban (anti-Xa) | 2 | √ | √ | 69.50 | 208 | ||
| Edoxaban (anti-Xa) | 2 | √ | √ | 69.50 | 221 | ||
| Argatroban (anti-IIa, dTT) | 2 | √ | √ | 69.50 | 209 | ||
| Dabigatran (anti-IIa, dTT) | 2 | √ | √ | 69.50 | 210 | ||
THROMBOELASTOGRAPHY PROGRAMME |
|||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
T1 |
T2 |
T3 |
T4 |
||||
| ROTEM delta ∗ 1 instrument / 1 set of samples ROTEM ∗ 2 instruments / 2 sets of samples ROTEM ∗ 3 instruments / 3 sets of samples ROTEM |
4 | √ | √ | √ | √ | 347.50 590.75 834.00 |
212 213 214 |
| ROTEM sigma ∗ 1 instrument / 1 set of samples ROTEM ∗ 2 instruments / 2 sets of samples ROTEM ∗ 3 instruments / 3 sets of samples ROTEM |
4 | √ | √ | √ | √ | 347.50 590.75 834.00 |
215 216 217 |
| TEG ∗ 1 instrument / 1 set of samples TEG ∗ 2 instruments / 2 sets of samples TEG ∗ 3 instruments / 3 sets of samples TEG |
4 | √ | √ | √ | √ | 347.50 590.75 834.00 |
218 219 220 |
| CLOT-PRO ∗ 1 instrument / 1 set of samples CLOT-PRO ∗ 2 instruments / 2 sets of samples CLOT-PRO ∗ 3 instruments / 3 sets of samples CLOT-PRO |
4 | √ | √ | √ | √ | 347.50 590.75 834.00 |
224 225 226 |
THROMBIN GENERATION PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
TG1 |
TG2 |
TG3 |
TG4 |
||||
| Thrombin Generation Test | 2 | √ | √ | 157.50 | 203 | ||
PFA PROGRAMME |
|||||||
Description |
Num-ber of sur-veys |
Survey(s)
|
Price
|
Product code |
|||
P1 |
P2 |
P3 |
P4 |
||||
| PFA-100/200 | 2 | √ | √ | 492.50 | 222 | ||
HIT PROGRAMME |
|||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
HIT1 |
HIT3 |
||||||
| HIT – I (immunological testing) | 2 | √ | √ | 235.00 | 204 | ||
ACT PROGRAMME
|
|||||||
| Note: samples will be distributed separately from other surveys. For details see Survey Schedule 2024 | |||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
ACT1 |
ACT2 |
||||||
| Activated Clotting Time | 2 | √ | √ | 132.50 | 504 | ||
POCT INR QC PROGRAMME |
|||||||
| No annual subscription fee applicable if only participating in the POCT INR QC Programme | |||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
Q1 |
Q2 |
Q3 |
Q4 |
||||
| POCT INR QC Programme for CoaguChek INR monitors (any type) |
4 | √ | √ | √ | √ | 473.00 | 301 |
| * Annual shipping costst for countries outside Europe: on request | |||||||
OTHER SURVEYS |
|||||
Description |
Organised
|
Num-
|
Survey
|
Price
|
Product code |
| Post Analytical Platelet Function EQA (electronic survey) | Nascola, USA | 2 | Spring, Autumn | 250.00 | 701 |
| Platelet Dense Granule exercise (electronic survey) | Nascola, USA | 2 | Spring, Autumn | 250.00 | 704 |
| Whole Blood Impedance Pleatelet Aggregation (electronic surveys) | Nascola, USA | 2 | Spring, Autumn | 220.00 | 707 |
| Case study on bleeding disorders (will be distributed together with survey 2024-3) | ECAT | 1 | 2024-3 | 115.00 | 703 |
| Case study on anticoagulation bridging (will be distributed together with survey 2024-2) | ECAT | 1 | 2024-2 | 115.00 | 706 |
| Pre- and post-analytical electronic survey in haemostasis | ECAT | 1 | Autumn | 80.00 | 705 |
HOMOCYSTEINE PROGRAMME
|
|||||||
Description |
Num-ber
|
Survey(s)
|
Price
|
Product code |
|||
01 |
02 |
03 |
04 |
||||
| Homocysteine | 4 | √ | √ | √ | √ | 185.00 | 1001 |
MOLECULAR BIOLOGY
|
||||||
MOLECULAR GENETICS MG1 |
||||||
Survey
|
Description |
Num-
|
Surveys
|
Price
|
Product
|
|
MG1
|
MG1
|
|||||
| MG1 Set A | For details: see below | 2 | √ | √ | ** | 601 |
| MG1 Set B | For details: see below | 2 | √ | √ | ** | 602 |
| MG1 Set C | For details: see below | 2 | √ | √ | ** | 603 |
| MG1 Set D | For details: see below | 2 | √ | √ | ** | 604 |
| MG1 Set E | For details: see below | 2 | √ | √ | ** | 605 |
| MG1 Set F | For details: see below | 2 | √ | √ | ** | 606 |
MOLECULAR GENETICS MG2 |
||||||
Survey
|
Description |
Num-
|
Surveys
|
Price
|
Product
|
|
MG2
|
MG2
|
|||||
| MG2 Set A | For details: see below | 2 | √ | √ | ** | 801 |
| MG2 Set B | For details: see below | 2 | √ | √ | ** | 802 |
| MG2 Set C | For details: see below | 2 | √ | √ | ** | 803 |
| MG2 Set D | For details: see below | 2 | √ | √ | ** | 804 |
| MG2 Set E | For details: see below | 2 | √ | √ | ** | 805 |
| MG2 Set F | For details: see below | 2 | √ | √ | ** | 806 |
PRICES MG1 OR MG2 |
||||||
| ** MG1 or MG2: one set: € 108.00, two sets: € 216.00, three sets: € 324.00 four sets: € 432.00, five sets: € 540.00, six sets: € 648.00 |
||||||
DNA SEQUENCING |
||||||
Survey
|
Description |
Num-
|
Surveys
|
Price
|
Product
|
|
SQ
|
SQ
|
|||||
| SQ | DNA Sequencing (Sequencing and corresponding diagnostic interpretation) | 2 | √ | √ | 264.00 | 901 |
DNA ISOLATION |
||||||
Survey
|
Description |
Num-ber
|
Surveys
|
Price
|
Product
|
|
DI
|
DI
|
|||||
| DI | DNA Isolation and genotyping For details: see below | 2 | √ | √ | 136.00 | 902 |
| Extra costs for shipment of Molecular Biology surveys | Per registration for one or more of the Molecular Biology surveys an annual fee of € 65.50 will be charged. |
| Details MG1 | ||
| Set A: | – FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025) – FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963) Methylenetetrahydrofolate reductase (MTHFR) – MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133) – MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131) – PAI-I 4G5G (SERPINE1, NM_000602.5:c.-820G[(4_5)], rs1799762) |
|
| Set B: | – FXIII V34L (F13A1, NM_000129.4:c.103G>T, rs5985) – GPIIIa (ITGB3, NM_000212.3:c.176T>C, rs5918) – beta-Fibrinogen g-455a (FGB, NM_005141.4:c.-463G>A, rs1800790) Vitamin K epoxide reductase complex subunit 1 (VKORC1) – VKORC1 G-1639 (VKORC1, NM_024006.6:c.-1639G>A, rs9923231) – VKORC1 C1173T (VKORC1, NM_024006.6:c.174-136C>T, rs9934438) – FXII c46t (F12, NM_000505.4:c.-4T>C rs1801020) – FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595) |
|
| Set C: | Alpha-1-Antitrypsin, (serpin family A member1) – AAT-PI*S (SERPINA1, NM_000295.5:c.863A>T, rs17580) – AAT-PI*Z (SERPINA1, NM_000295.5:c.1096G>A, rs28929474) – AAT- (Alpha-1-Antitrypsin-Genotyping) Apolipoprotein E (APOE) – ApoE2 (APOE, NM_000041.4:c.526C>T, rs7412) – ApoE4 (APOE, NM_000041.4:c.388T>C, rs429358) – ApoE (Apolipoprotein E – Genotyping) – ApoB100 (APOB, NM_000384.3:c.10580G>A, rs5742904) – ACE I/D (ACE, NM_000789.3:c.2306-117_2306-116insAF118569.1:g.14094_14382, rs1799752) – CETP B1/B2 (CETP, NM_000078.3:c.118+279G>A, rs708272 |
|
| Set D: | Aldolase, fructose-bisphosphate B (ALDOB ) – AldoB 149 (ALDOB, NM_000035.4:c.448G>C, rs1800546) – AldoB 174 (ALDOB, NM_000035.4:c.524C>A, rs76917243) – AldoB 334 (ALDOB, NM_000035.4:c.1005C>G, rs78340951) Hereditary Hemochromatosis (HFE) – HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945) – HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730) – HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562) – LCT c-13910t (LCT, NM_005915.6:c.1917+326C>T, rs4988235) Nucleotide binding oligomerization domain containing 2 (NOD2) – NOD R702W (NOD2, NM_001370466.1:c.2023C>T, rs2066844) – NOD G908R (NOD2, NM_001370466.1:c.2641G>C, rs2066845) – NOD L1007finsC (NOD2, NM_001370466.1:c.2938dup, rs2066847) |
|
| Set E: | – ATP7B-C3207A (ATP7B, NM_000053.4:c.3207C>A, rs76151636) – FSAP Marburg-I (HABP2, NM_004132.5:c.1601G>A, rs7080536) – ITGA2 GpIaIIa C807T (ITGA2, NM_002203.4:c.759C>T, rs1126643) – Col1A1 SP1 (Col1A1, NM_000088.4:c.104-441G>T, rs1800012) Vitamin D receptor (VDR) – VDR BsmI (VDR, NM_000376.3:c.1024+283G>A, rs1544410) – VDR ApaI (VDR, NM_000376.3:c.1025-49G>T, rs7975232) – VDR TaqI (VDR, NM_000376.3:c.1056T>C, rs731236) |
|
| Set F: | – Faktor VII (R353Q) (F7, NM_019616.4:c.1172G>A, rs6046) – AT3 Cambridge Typ I/II (SERPINC1, NM_000488.4:c.1246G>C>T, rs121909548) – CYP3A5*3 (CYP3A5, NM_000777.5:c.219-237A>G, rs776746) |
|
| Details MG2 | |
| Set A: | Thiopurine S-methyltransferase (TPMT) – TPMT*2 (TPMT, NM_000367.5:c.238G>C, rs1800462) – TPMT*3B (TPMT, NM_000367.5:c.460G>A, rs1800460) – TPMT*3C (TPMT, NM_000367.5:c.719A>G, rs1142345) – Thiopurine S-methyltransferase (TPMT –Genotyping) – CYP2C8*3 (CYP2C8, NM_000770.3:c.1196A>G, rs10509681) Cytochrom P450 2C9 (CYP2C9) – CYP2C9*2 (CYP2C9, NM_000771.4:c.430C>T, rs1799853) – CYP2C9*3 (CYP2C9, NM_000771.4:c.1075A>C, rs1057910) – CYP2C9 (2C9 – Genotyping) – UGT1A1*28 (UGT1A1, NM_000463.3:c.-41_-40dupTA, rs3064744) Dihydropyrimidine dehydrogenase (DPYD) – DPYD*2A (DPYD, NM_000110.4:c.1905+1G>A, rs3918290) – DPYD*13 (DPYD, NM_000110.4:c.1679T>G, rs55886062) – DPYD p.D949V (DPYD, NM_000110.4:c.2846A>T, rs67376798) – DPYD c.1129-5923C>G (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182) – DPYD c.1236G>A (DPYD, NM_000110.4:c.1236G>A, rs56038477) – DPYD HapB3 (DPYD, NM_000110.4:c.1129-5923C>G, rs75017182, NM_000110.4:c.1236G>A, rs56038477) – DPD activity score acc. to CPIC – DPD activity score acc. to DGHO – BCHE A (D70G) (BCHE, NM_000055.4:c.293A>G, rs1799807) – BCHE K (A567T) (BCHE, NM_000055.4:c.1699G>A, rs1803274) |
| Set B: | KRAS proto-oncogene, GTPase (KRAS) – KRAS p.G12/p.G13 (KRAS, NP_004976.2:p.G12/G13) – KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530) – KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529) – KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535) – KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441) – KRAS p.G12 (KRAS, NP_004976.2:p.G12) – KRAS p.G12 (KRAS, NM_004985.5:c.34G>T>C>A, rs121913530) – KRAS p.G12 (KRAS, NM_004985.5:c.35G>T>C>A, rs121913529) – KRAS p.G13 (KRAS, NP_004976.2:p.G13) – KRAS p.G13 (KRAS, NM_004985.5:c.37G>T>C>A, rs121913535) – KRAS p.G13 (KRAS, NM_004985.5:c.38G>T>C>A, rs112445441) – KRAS p.Q61 (KRAS, NP_004976.2:p.Q61) – KRAS p.Q61 (KRAS, NM_004985.5:c.181C>G>A, rs121913238) – KRAS p.Q61 (KRAS, NM_004985.5:c.182A>T>G>C, rs121913240) – KRAS p.Q61 (KRAS, NM_004985.5:c.183A>T>C, rs17851045) BRAF p.V600 (BRAF, NP_004324.2:p.V600E/K, rs113488022, rs121913227) – NM_004333.6:c.1799T>A, rs113488022 – NM_004333.6:c.1798_1799delinsAA, rs121913227 – cKIT p.D816V (KIT, NM_000222.3:c.2447A>T, rs121913507) NRAS (NRAS, NP_002515.1:p.Q61) – NRAS (NRAS, NM_002524.5:c.181C>T>G>A, rs121913254) – NRAS (NRAS, NM_002524.5:c.182A>T>G>C, rs11554290) – NRAS (NRAS, NM_002524.5:c.183A>T>C, rs121913255) |
| Set C: | – HLA-B*27 (HLA-B, NM_005514.8) – TNF alpha 238 (TNF, NM_000594.3:c.-418G>A, rs361525) – TNF alpha 308 (TNF, NM_000594.3:c.-488G>A, rs1800629) |
| Set D: | Cytochrome P450 2D6 (CYP2D6) – CYP2D6*2-296 (CYP2D6*2, NM_000106.6:c.886C>T, rs16947) – CYP2D6*2-486 (CYP2D6*2, NM_000106.6:c.1457G>C, rs1135840) – CYP2D6*3 (CYP2D6*3, NM_000106.6:c.775del, rs35742686) – CYP2D6*4 (CYP2D6*4, NM_000106.6:c.506-1G>A, rs3892097) – CYP2D6*6 (CYP2D6*6, NM_000106.6:c.454del, rs5030655) – CYP2D6*7 (CYP2D6*7, NM_000106.6:c.971A>C, rs5030867) – CYP2D6*8 (CYP2D6*8, NM_000106.6:c.505G>T, rs5030865) – CYP2D6*9 (CYP2D6*9, NM_000106.6:c.841_843del, rs5030656) – CYP2D6*10 (CYP2D6*10, NM_000106.6:c.100C>T, rs1065852) – CYP2D6*17 (CYP2D6*17, NM_000106.6:c.320C>T, rs28371706) – CYP2D6*35 (CYP2D6*35, NM_000106.6:c.31G>A, rs769258) – CYP2D6*41 (CYP2D6*41, NM_000106.6:c.985+39G>A, rs28371725) – CYP2D6*5 (CYP2D6, Deletion) – CYP2D6*xN (CYP2D6, Duplication/Amplification) Cytochrome P450 2C19 (CYP2C19) – CYP2C19*2 (CYP2C19, NM_000769.4:c.681G>A, rs4244285) – CYP2C19*3 (CYP2C19, NM_000769.4:c.636G>A, rs4986893) – CYP2C19*17 (CYP2C19, NM_000769.4:c.-806C>T, rs12248560) – CYP2C19 Genotyping |
| Set E: | – HLA B*57:01 (HLA-B, NM_005514.8) Cytochrome P450 2B6 (CYP2B6) – CYP2B6*4 (CYP2B6, NM_000767.5:c.785A>G, rs2279343) – CYP2B6*9 (CYP2B6, NM_000767.5:c.516G>T, rs3745274) – CYP2B6*6 (CYP2B6, NM_000767.5:c.785A>G, rs2279343+NM_000767.5:c.516G>T, rs3745274) – ABCB1 c.3435T>C (ABCB1, NM_001348946.2:c.3435T>C, rs1045642) – CCR5-del32bp (CCR5, NM_001394783.1:c.554_585del, rs333) |
| Set F: | – IL28B (C/T Polymorphism) (IFNL4, NM_001276254.2:c.151-152G>A, rs12979860) – IL6 G(-174)C (IL6, NM_000600.4:c.-237C>G, rs1800795) – CYP3A4*22 (CYP3A4, NM_017460.6:c.522-191C>T, rs35599367) |
| Details DNAIsolation and genotyping | |
| Set: | – FV-Leiden (F5, NM_000130.5:c.1601G>A, rs6025) – FV-H1299R (F5, NM_000130.5:c.3980A>G, rs1800595) – FV-Cambridge (F5, NM_000130.5:c.1001G>C, rs118203906) – FV-Hong-Kong (F5, NM_000130.5:c.1000A>G, rs118203905) – FII g20210a (F2, NM_000506.5:c.*97G>A, rs1799963) Methylenetetrahydrofolate reductase (MTHFR) – MTHFR C677T (MTHFR, NM_005957.5:c.665C>T, rs1801133) – MTHFR A1298C (MTHFR, NM_005957.5:c.1286A>C, rs1801131) Hereditary Hemochromatosis (HFE) – HFE H63D (HFE, NM_000410.4:c.187C>G, rs1799945) – HFE S65C (HFE, NM_000410.4:c.193A>T, rs1800730) – HFE C282Y (HFE, NM_000410.4:c.845G>A, rs1800562) |